Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pacific Edge Limited ( (PFGTF) ) is now available.
Pacific Edge Limited has issued 625,000 ordinary shares at a nominal price of NZD $0.10 per share, as non-cash consideration for legal advisory services provided during a recent capital raise. This issuance, representing 0.061% of the total class of shares, was approved by the board and aligns with NZX Listing Rule 4.5.1. The move reflects the company’s strategy to manage operational costs effectively while rewarding service providers, potentially strengthening its financial position and stakeholder relationships.
More about Pacific Edge Limited
Pacific Edge Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic tests for the early detection and management of cancer. The company is known for its innovative solutions in cancer diagnostics, particularly in the area of bladder cancer.
For a thorough assessment of PFGTF stock, go to TipRanks’ Stock Analysis page.